Showing results for:
Belantamab mafodotin-blmf is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Blenrep Belantamab mafodotin-blmf
Belinostat is FDA approved for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Beleodaq™ Belinostat
Rezurock™ is approved for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
Rezurock™ Belumosudil
Bendamustine hydrochloride is FDA approved to treat people who have:Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Treanda® Bendamustine hydrochloride Bendeka™
Bexarotene is FDA approved to treat people who have skin problems arising from cutaneous T-cell lymphoma (CTCL) in patients who are refractory for at least one prior systemic therapy. It may be used after other drugs have been tried and the tumor is still a problem.
Targretin® Bexarotene
Bleomycin is FDA approved as a single agent or in proven combinations to treat people who have Hodgkin and non-Hodgkin lymphoma. Bleomycin may cause a temporary loss of hair in some people. Normal hair growth should return after treatment ends (although it may take several months).
Blenoxane® Bleomycin
Blinatumomab is FDA approved for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.
Blincyto® Blinatumomab
Bortezomib is FDA approved to treat people with myeloma and for the retreatment of adult patients with myeloma who had previously responded to bortezomib therapy and relapsed at least six months following completion of prior bortezomib treatment. Bortezomib is also approved to treat people with previously untreated mantle cell lymphoma as well as patients who have received at least one prior therapy.
Velcade® Bortezomib
Bosutinib is FDA approved for the treatment ofAdult and pediatric patients 1 year of age and older with chronic phase Ph+ chronic myelogenous leukemia (CML), newly diagnosed or resistant or intolerant to prior therapy.Adult patients with accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
Bosulif® Bosutinib
Brentuximab vedotin is FDA approved for the treatment of:Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral Tcell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone.Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product.
Adcetris® Brentuximab vedotin
Brexucabtagene autoleucel is FDA approved for the treatment ofAdult patients with relapsed or refractory mantle cell lymphoma (MCL).This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Tecartus® Brexucabtagene autoleucel
Busulfan is FDA approved in combination with cyclophosphamide as a conditioning regimen prior to allogeneic stem cell transplantation for people who have chronic myeloid leukemia.
Busulfex® Myleran® Busulfan
Carmustine is FDA approved to treat people who have myeloma (in combination with prednisone); relapsed or refractory Hodgkin lymphoma (as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy or who fail to respond to primary therapy); relapsed or refractory non-Hodgkin lymphoma (as secondary therapy in combination with other approved drugs).
BiCNU® BCNU Carmustine
Inotuzumab ozogamicin is FDA approved for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older.
Besponsa® Inotuzumab Ozogamicin
Interferons are substances naturally produced by cells in the body to help fight infections and tumors. They may also be synthetic versions of these substances.Interferon alfa-2b is FDA approved to treat people who have hairy cell leukemia, polycythemia vera and aggressive follicular non-Hodgkin lymphoma.
Intron® A Interferon alfa-2b BESREMi®
Lisocabtagene maraleucel is indicated for the treatment ofAdult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have: Refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age; or Relapsed or refractory disease after two or more lines of systemic therapy. Limitations of Use: Lisocabtagene maraleucel is not indicated for the treatment of patients with primary central nervous system lymphoma.Adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor.This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).Adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.
Breyanzi® Lisocabtagene maraleucel
Zanubrutinib is indicated for the treatment of adult patients with:Mantle cell lymphoma (MCL) who have received at least one prior therapy.This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.Waldenström’s macroglobulinemia (WM)Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy.This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Brukinsa® Zanubrutinib